Thus, we suspect that USP10 could reduce the DDR and stabilize mutp53 to promote tumor progression, and confers cisplatin resistance via HDAC6 in the mutp53 subset of NSCLC (Figure 1). Here, HDAC6 is linked to non-small cell lung carcinoma.